全文获取类型
收费全文 | 13716篇 |
免费 | 785篇 |
国内免费 | 44篇 |
专业分类
耳鼻咽喉 | 164篇 |
儿科学 | 271篇 |
妇产科学 | 294篇 |
基础医学 | 1869篇 |
口腔科学 | 330篇 |
临床医学 | 1018篇 |
内科学 | 2976篇 |
皮肤病学 | 278篇 |
神经病学 | 1352篇 |
特种医学 | 339篇 |
外科学 | 2121篇 |
综合类 | 51篇 |
一般理论 | 3篇 |
预防医学 | 724篇 |
眼科学 | 314篇 |
药学 | 1064篇 |
中国医学 | 59篇 |
肿瘤学 | 1318篇 |
出版年
2023年 | 99篇 |
2022年 | 57篇 |
2021年 | 248篇 |
2020年 | 183篇 |
2019年 | 293篇 |
2018年 | 325篇 |
2017年 | 293篇 |
2016年 | 335篇 |
2015年 | 336篇 |
2014年 | 384篇 |
2013年 | 557篇 |
2012年 | 857篇 |
2011年 | 910篇 |
2010年 | 454篇 |
2009年 | 449篇 |
2008年 | 710篇 |
2007年 | 754篇 |
2006年 | 700篇 |
2005年 | 707篇 |
2004年 | 662篇 |
2003年 | 667篇 |
2002年 | 618篇 |
2001年 | 345篇 |
2000年 | 398篇 |
1999年 | 333篇 |
1998年 | 104篇 |
1997年 | 78篇 |
1996年 | 65篇 |
1995年 | 72篇 |
1994年 | 68篇 |
1993年 | 66篇 |
1992年 | 226篇 |
1991年 | 192篇 |
1990年 | 230篇 |
1989年 | 211篇 |
1988年 | 196篇 |
1987年 | 192篇 |
1986年 | 204篇 |
1985年 | 146篇 |
1984年 | 115篇 |
1983年 | 80篇 |
1982年 | 36篇 |
1981年 | 38篇 |
1980年 | 35篇 |
1979年 | 82篇 |
1978年 | 60篇 |
1977年 | 45篇 |
1974年 | 44篇 |
1973年 | 38篇 |
1972年 | 37篇 |
排序方式: 共有10000条查询结果,搜索用时 31 毫秒
1.
Tanaka Mari Kawai Natsuko Yuasa Norihiro 《International journal of clinical oncology / Japan Society of Clinical Oncology》2022,27(4):655-664
International Journal of Clinical Oncology - Some studies have developed a scoring system to determine the short-term survival of patients with respiratory malignancy. A total of 649 terminally ill... 相似文献
2.
Herkama Sanna Kontio Mari Sainio Miia Turunen Tiina Poskiparta Elisa Salmivalli Christina 《Prevention science》2022,23(6):954-968
Prevention Science - The long-term sustainment of bullying prevention programs has rarely been investigated. This study addresses this gap by identifying facilitators and barriers to the systematic... 相似文献
3.
Takano Fumio Mori Sotaro Okuda Mina Murai Yusuke Ueda Kaori Sakamoto Mari Kurimoto Takuji Yamada-Nakanishi Yuko Nakamura Makoto 《Albrecht von Graefes Archiv fur klinische und experimentelle Ophthalmologie》2022,260(11):3607-3615
Graefe's Archive for Clinical and Experimental Ophthalmology - The purpose of this retrospective study was to determine the extent to which the use of antithrombotic drugs during glaucoma... 相似文献
4.
Takehiko Mori Souichi Shiratori Junji Suzumiya Mineo Kurokawa Motohiro Shindo Uchida Naoyuki Takenaka Katsuto Toshihiro Miyamoto Satoshi Morishige Makoto Hirokawa Takahiro Fukuda Yoshiko Atsuta Ritsuro Suzuki 《Hematological oncology》2020,38(3):266-271
Although allogeneic hematopoietic stem cell transplantation (HSCT) has been reported to provide prolonged remission of relapsed/refractory mycosis fungoides (MF) and Sézary syndrome (SS), its role has not been fully evaluated. Here, the outcomes of allogeneic HSCT for patients with MF/SS were retrospectively evaluated by using the registry database of the Japan Society for Hematopoietic Cell Transplantation. Forty-eight patients were evaluable and enrolled in the analysis. Median age was 45.5 years. Eighteen patients (38%) received myeloablative conditioning, and 33 (69%) received HSCT from an alternative donor. Disease status was complete or partial response in 25% of the patients and relapsed or refractory in the others. At the time of analysis, 18 patients were alive, with a median follow-up of 31.0 months (range, 3.8-31.1). Three-year overall survival (OS) and progression-free survival (PFS) were 30% (95%CI, 16-45%) and 19% (95%CI, 9-31%), respectively. Disease progression was not observed later than 17 months after transplantation. Both disease status and performance status at transplant significantly affected OS and PFS. Although our findings suggest that allogeneic HSCT provides long-term PFS in patients with MF/SS, the timing of transplantation should be decided carefully based on the disease status and the patient's condition in order to improve the outcome. 相似文献
5.
6.
7.
Ritva Ahomäki Andreina Kero Mari Koivisto Laura Madanat-Harjuoja Nea Malila Päivi M. Lähteenmäki 《International journal of cancer. Journal international du cancer》2019,144(6):1227-1233
According to previous studies, childhood cancer survivors have an elevated risk for late mental health effects. However, only few studies exist on young adulthood (YA) cancer survivors’ mental health outcomes. In our study, we examined first time antidepressant (AD) medication purchases of childhood and YA cancer patients compared to siblings. The first time AD medication purchases of 7,093 cancer patients aged 0–34 years at diagnosis and a sibling cohort (N = 26,882) were retrieved from the Social Insurance Institution of Finland (Kela) since 1.1.1993. Cancer patients diagnosed between 1.1.1994 and 31.12.2004 were identified from the Finnish Cancer Registry and sibling controls via the Population Registry Centre. Statistical analyses were performed via the Cox regression model, and the hazard ratios (HR) were adjusted for age and gender. Increased hazard ratios for AD purchases were found in the younger (0–19 years at cancer diagnosis) [HR 5.2, 95%CI (3.7–7.2)] and older (age 20–34 years at cancer diagnosis) [HR 4.5, 95%CI (3.9–5.2)] cancer patient groups compared to siblings. The gender effect was similar in patients and controls, showing that females have higher risk for AD purchases than males. Males in the younger patient group had highest HR (5.6) for AD purchases compared to siblings. Patients with sarcoma or CNS tumor in the younger age group and leukemia or CNS malignancy in the older age group had the highest risk for AD medication purchases. The frequency and risk for AD purchases has been increasing during recent decades in both cancer patient age groups compared to siblings. Thus, cancer patients’ psychological support should be properly assessed already after primary treatment. Certain diagnostic groups as well as female patients may require more psychological support than others. 相似文献
8.
Hiroaki Soyama Morikazu Miyamoto Hiroko Matsuura Hideki Iwahashi Soichiro Kakimoto Hiroki Ishibashi Takahiro Sakamoto Taira Hada Jin Suminokura Masashi Takano 《Cancer chemotherapy and pharmacology》2020,85(5):941-947
The aim of this study was to investigate the association between changes in the levels of vascular endothelial growth factors (VEGFs) after treatment with bevacizumab and gemcitabine (Bev-Gem) and the clinical outcome. Platinum-resistant ovarian cancer patients treated with Bev-Gem therapy at our hospital between 2014 and 2018 were identified. Serum VEGF levels at the first and second treatment cycle were measured by ELISA. All patients were categorized into two groups—patients with > 50% decrease in serum VEGF-A levels (Group A) and patients with < 50% decrease serum VEGF-A levels (Group B). The association between clinical outcome and serum VEGF levels was investigated between the two groups. Among 18 patients, 10 were in Group A and 8 in Group B. Group A exhibited a lower response rate (0% vs.75% p < 0.01) and clinical benefit rate (60% vs.100% p = 0.02) than Group B. The median serum VEGF-A level of Group A before the first cycle of Bev-Gem therapy was higher than that in Group B (61.2 vs. 3.7 pg/mL, p < 0.01). Group A exhibited worse PFS (7 vs., 10 months, p < 0.01) and OS (17 vs. 26 months, p = 0.04) than Group B. There were more patients with > 10% increase in serum VEGF-B levels in Group A than in Group B (p < 0.01). The rapid decrease in VEGF-A levels and the resultant increase in serum VEGF-B levels might be associated with an unfavorable clinical outcome. Large-scale studies are needed to further examine these results. 相似文献
9.
Matthew J. Stubbs Ryan Low Siobhan McGuckin Rosalind Newton Mari Thomas John P. Westwood Raakhee Shah Simon Cheesman Marie A. Scully 《British journal of haematology》2019,185(5):912-917
Immune thrombotic thrombocytopenic purpura (iTTP) is an acute, multisystem thrombotic microangiopathy mediated by ADAMTS13 (a disintegrin and metalloproteinase with a thrombospondin type 1 motif, member 13) autoantibodies. Immunosuppression with anti-CD20 therapy is the mainstay of treatment. MabThera's patent has now expired and biosimilars have been approved. Eighty-four consecutive patient episodes over 2 years, prior to and following our switch to Truxima are presented. Day 1 (D1), Day 28 (D28) and 3-month platelet counts, ADAMTS13 activity, and CD19 levels, adverse reactions and infective complications were recorded. Platelet counts were not significantly different between acute MabThera and Truxima treatment (D1 P = 0.085, D28 P = 0.77, 3 months P = 0.71) and electively (D1 P = 0.79, D28 P = 0.68, 3 months P = 0.99). ADAMTS13 recovery also was not significantly different acutely (D1 P = 0.99, D28 P = 0.27, 3 months P = 0.26) and electively (D1 P = 0.59, D28 P = 0.61, 3 months P = 0.34). CD19% depletion at D1 and 3 months was not significantly different acutely (D1 P = 0.52, 3 months P = 0.56) and electively (D1 P = 0.22, 3 months P = 0.19). Infusion reactions and infective complications were comparable with both therapies. This is the first series of the Rituximab biosimilar Truxima to be reported in iTTP, demonstrating equivalence to MabThera in terms of ADAMTS13 recovery, CD19 depletion, and platelet count at D28 and 3 months post-administration, with comparable infusion and infective complications. The financial benefit of the biosimilar anti-CD20 is considerable. 相似文献
10.